FI115697B - Förfarande för framställning av en hydrogel bildande långsamt frigörande preparat - Google Patents
Förfarande för framställning av en hydrogel bildande långsamt frigörande preparat Download PDFInfo
- Publication number
- FI115697B FI115697B FI951226A FI951226A FI115697B FI 115697 B FI115697 B FI 115697B FI 951226 A FI951226 A FI 951226A FI 951226 A FI951226 A FI 951226A FI 115697 B FI115697 B FI 115697B
- Authority
- FI
- Finland
- Prior art keywords
- drug
- preparation
- hydrogel
- weight
- tablets
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (14)
1. Förfarande för framställning av en hydrogel bildande längsamt frigörande prepa-rat i tablett- eller kapselform för oralt bruk, vilket preparat uppvisar ett gelatine-5 rings-index pä 70% eller mera, kännetecknat därav, att man tar: (1) ätminstone ett läkemedel, vars totalmängd inte överskrider 85 viktprocen-ta av preparatets totalvikt, 10 (2) ätminstone ett tillsatsämne, som säkerställer vattnets inträngning i prepa-ratet och vars löslighet är sädan, att den vattenmängd, som erfordras för att lösa ett gram tillsatsmedel, inte är större än 5 ml, vilket nämnda tillsatsmedels totalmängd är 5 - 80% viktprocent av preparatets totalvikt, och 15 (3) ätminstone en hydrogel bildande polymer, vars medelmolekylvikt är ätminstone 2 000 000 eller dess viskositet är minst 1000 cps mätt som 1% koncent-ration i vatten 25 °C, varvid nämnda hydrogel bildande polymers totalmängd är 10 - 95 viktprocent beräknad pä preparatets totalmängd och minst 70 mg 20 per tablett eller kapsel, varvid komponenterna 1), 2) och 3) blandas sinsemellan, smörjmedel tillsätts even-; tuellt, varefter blandning komprimeras. 25
2. Förfarande enligt patentkravet 1, kännetecknat därav, att nämnda tillsatsme- : dels löslighet är sädan, att den vattenmängd, som erfordras för att lösa 1 g nämnda ’ tillsatsmedel, inte är större än 4 ml. i
3. Förfarande enligt patentkravet 1 eller 2, kännetecknat därav, att läkemedlets * 30 mängd är mindre än 80%, nämnda tillsatsmedels mängd är 5 - 60%, och hydroge- ;· Ien bildande polymerens mängd är 15 - 90%, alla vikter baserar sig pä preparatets totalmängd. I 1 * % • 115697
4. Förfarande enligt nlgot av föregäende patentkrav, kännetecknat därav, att nämnda hydrogel bildande polymers mängd är minst 100 mg per tablett eller kap-sel.
5 5. Förfarande enligt nägot av föregäende patentkrav, kännetecknat därav, att som läkemedel används nikardipinhydroklorid eller tamusulocinhydroklorid.
6. Förfarande enligt nägot av föregäende patentkrav, kännetecknat därav, att nämnda tillsatsmedel valts ur gruppen bestäende av polyetylenglykol, polyvinylpyr-10 rolidon, D-sorbitol, xylitol, sackaros, vattenfri maltos, D-fruktos, dextran, polyoxiety-lenhydrogenerad kastor-olja, polyoxietylenpolyoxipropylenglykol, polyoxietylen-sor-bitans höga fettsyraester, natriumklorid, magnesiumklorid, citronsyra, vinsyra, gly-cin, p-alanin, lysinhydroklorid och meglumin. 15
7. Förfarande enligt patentkravet 6, kännetecknat därav, att nämnda tillsatsmedel valts ur gruppen polyetylenglykol, polyvinylpyrrolidon och D-sorbitol.
8. Förfarande enligt patentkravet 7, kännetecknat därav, att nämnda tillsatsmedel är polyetylenglykol. 20
9. Förfarande enligt nägot av föregäende patentkrav, kännetecknat därav, att ,' nämnda hydrogel bildande polymer är vald ur gruppen bestäende av polyetylenoxid, ; ; hydroxipropylmetylcellulosa, natriumkarboximetylcellulosa, hydroxietylcellulosa och '· karboxivinylpolymerer. 25
: : 10. Förfarande enligt patentkravet 9, kännetecknat därav, att nämnda hydrogel ' bildande polymer är polyetylenoxid.
: 11. Förfarande enligt patentkravet 1, kännetecknat därav, att komponenterna 1), 30 2) och 3) granuleras, kornen torkas eventuellt, smörjmedel tillsätts eventuellt, och ! · blandning komprimeras.
12. Förfarande enligt patentkrav 11, kännetecknat därav, att komponenterna 1) ’. och 2) granuleras, komponenten 3) tillsätts kornen, smörjmedel tillsätts eventuellt, 35 och blandning komprimeras. 115697
13. Patentkrav 11 enligt förfarande, kännetecknat därav, att komponenterna 2) och 3) granuleras, komponenten 1) tillsätts kornen, smörjmedel tillsätts eventuellt, och blandning komprimeras. 5
14. Förfarande enligt patentkrav 12, kännetecknat därav, att komponenterna 1) och 2) loses, den erhällna lösningen ansluts tili komponenten 3) genom spraygranulering, smörjmedel tillsätts eventuellt, och blandning komprimeras. » t
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP27497992 | 1992-09-18 | ||
JP27497992 | 1992-09-18 | ||
JP16526393 | 1993-06-08 | ||
JP16526393 | 1993-06-08 | ||
JP9301297 | 1993-09-10 | ||
PCT/JP1993/001297 WO1994006414A1 (en) | 1992-09-18 | 1993-09-10 | Sustained-release hydrogel preparation |
Publications (3)
Publication Number | Publication Date |
---|---|
FI951226A0 FI951226A0 (sv) | 1995-03-16 |
FI951226A FI951226A (sv) | 1995-03-16 |
FI115697B true FI115697B (sv) | 2005-06-30 |
Family
ID=26490061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI951226A FI115697B (sv) | 1992-09-18 | 1995-03-16 | Förfarande för framställning av en hydrogel bildande långsamt frigörande preparat |
Country Status (23)
Country | Link |
---|---|
US (3) | US6436441B1 (sv) |
EP (1) | EP0661045B1 (sv) |
JP (1) | JP3140465B2 (sv) |
KR (1) | KR100355130B1 (sv) |
CN (1) | CN1048397C (sv) |
AT (1) | ATE219933T1 (sv) |
AU (1) | AU682827B2 (sv) |
BG (1) | BG61861B1 (sv) |
CA (1) | CA2144077C (sv) |
CZ (1) | CZ291495B6 (sv) |
DE (1) | DE69332081T2 (sv) |
DK (1) | DK0661045T3 (sv) |
ES (1) | ES2179829T3 (sv) |
FI (1) | FI115697B (sv) |
HU (1) | HU226456B1 (sv) |
NO (1) | NO312811B1 (sv) |
NZ (1) | NZ255579A (sv) |
PL (1) | PL175026B1 (sv) |
PT (1) | PT661045E (sv) |
RO (1) | RO112991B1 (sv) |
RU (1) | RU2121830C1 (sv) |
SK (1) | SK281042B6 (sv) |
WO (1) | WO1994006414A1 (sv) |
Families Citing this family (162)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ291495B6 (cs) * | 1992-09-18 | 2003-03-12 | Yamanouchi Pharmaceutical Co., Ltd. | Hydrogelotvorný farmaceutický přípravek s prodlouženým uvolňováním |
DE19509807A1 (de) * | 1995-03-21 | 1996-09-26 | Basf Ag | Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen |
US5945125A (en) * | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
US6166024A (en) | 1995-03-30 | 2000-12-26 | Mayo Foundation For Medical Education And Research | Use of topical azathioprine and thioguanine to treat colorectal adenomas |
EP0761209A3 (en) * | 1995-09-01 | 1998-02-04 | J.B. Chemicals & Pharmaceuticals Ltd. | Controlled release formulations of ranitidine |
WO1997049384A1 (en) * | 1996-06-26 | 1997-12-31 | Board Of Regents, The University Of Texas System | Hot-melt extrudable pharmaceutical formulation |
AU3444297A (en) * | 1996-07-12 | 1998-02-09 | Novartis Consumer Health S.A. | Oral pharmaceutical combinations of nsaids with terpenoids |
GB9720797D0 (en) * | 1997-09-30 | 1997-12-03 | Rhodes John | Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome |
US20040029962A1 (en) * | 1997-12-12 | 2004-02-12 | Chih-Ming Chen | HMG-COA reductase inhibitor extended release formulation |
US20060141036A1 (en) * | 1997-12-12 | 2006-06-29 | Andrx Labs Llc | HMG-CoA reductase inhibitor extended release formulation |
SE9704869D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulaton II |
DE19901040A1 (de) * | 1999-01-14 | 2000-07-20 | Knoll Ag | Arzneiformen mit gesteuerter Freisetzung, enthaltend gut wasserlösliche Wirkstoffe |
EG23951A (en) | 1999-03-25 | 2008-01-29 | Otsuka Pharma Co Ltd | Cilostazol preparation |
EP1183010A2 (en) * | 1999-06-04 | 2002-03-06 | ALZA Corporation | Implantable gel compositions and method of manufacture |
US6562375B1 (en) | 1999-08-04 | 2003-05-13 | Yamanouchi Pharmaceuticals, Co., Ltd. | Stable pharmaceutical composition for oral use |
YU35302A (sh) * | 1999-12-23 | 2005-03-15 | Pfizer Products Inc. | Dozirani oblik leka sa inicijalnim hidrogelom |
AU2001250646A1 (en) * | 2000-04-17 | 2001-10-30 | Yamanouchi Pharmaceutical Co..Ltd. | Drug delivery system for avoiding pharmacokinetic interaction between drugs and method thereof |
US20020028240A1 (en) * | 2000-04-17 | 2002-03-07 | Toyohiro Sawada | Timed-release compression-coated solid composition for oral administration |
US6419954B1 (en) * | 2000-05-19 | 2002-07-16 | Yamanouchi Pharmaceutical Co., Ltd. | Tablets and methods for modified release of hydrophilic and other active agents |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
PE20030527A1 (es) | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
US20030091630A1 (en) * | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
US20030152622A1 (en) * | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
MXPA04004544A (es) * | 2001-11-13 | 2005-03-31 | Yamanouchi Pharma Tech Inc | Sistema de liberacion prolongada para droga soluble. |
JP2005523262A (ja) | 2002-02-01 | 2005-08-04 | ファイザー・プロダクツ・インク | 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物 |
WO2003072085A1 (fr) * | 2002-02-27 | 2003-09-04 | Shionogi & Co., Ltd. | Preparations solides contenant un medicament a peine soluble dans l'eau d'une meilleure absorbabilite |
NZ519363A (en) * | 2002-06-05 | 2004-02-27 | Agres Ltd | A novel drug dosing regimen |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
US8679533B2 (en) | 2002-07-25 | 2014-03-25 | Pharmacia Corporation | Pramipexole once-daily dosage form |
AU2003262059A1 (en) | 2002-09-11 | 2004-04-30 | Takeda Pharmaceutical Company Limited | Sustained release preparation |
MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
JP4459543B2 (ja) | 2003-03-17 | 2010-04-28 | 株式会社メドジェル | 徐放性ハイドロゲル製剤 |
BRPI0413277A (pt) | 2003-08-04 | 2006-10-10 | Pfizer Prod Inc | composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas |
DE102005005446A1 (de) * | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102004020220A1 (de) * | 2004-04-22 | 2005-11-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE10336400A1 (de) * | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE102004032051A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
US8128958B2 (en) * | 2003-11-10 | 2012-03-06 | Astellas Pharma Inc. | Sustained release pharmaceutical composition |
US8197846B2 (en) | 2003-11-10 | 2012-06-12 | Astellas Pharma Inc. | Sustained release pharmaceutical composition |
US20050171248A1 (en) * | 2004-02-02 | 2005-08-04 | Yanmei Li | Hydrogel for use in downhole seal applications |
EP1750717B1 (en) * | 2004-02-11 | 2017-07-19 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
ES2653568T3 (es) | 2004-06-12 | 2018-02-07 | Collegium Pharmaceutical, Inc. | Formulaciones de fármacos para la prevención del abuso |
DE102004032049A1 (de) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
US7409999B2 (en) * | 2004-07-30 | 2008-08-12 | Baker Hughes Incorporated | Downhole inflow control device with shut-off feature |
CA2576386A1 (en) | 2004-08-13 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
ATE486588T1 (de) | 2004-08-13 | 2010-11-15 | Boehringer Ingelheim Int | Tablettenformulierung mit verlängerter freisetzung mit pramipexol oder einem pharmazeutisch zulässigen salz davon, herstellungsverfahren und verwendung dafür |
US20060074182A1 (en) | 2004-09-30 | 2006-04-06 | Depuy Products, Inc. | Hydrogel composition and methods for making the same |
EP1712230A1 (en) * | 2004-10-05 | 2006-10-18 | Astellas Pharma Inc. | Pharmaceutical composition for xerophthalmia and xerostomia treatment |
CA2588017A1 (en) * | 2004-12-13 | 2006-06-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Use of alpha-adrenergic blockers for the treatment of dysmenorrhea |
DE102005005449A1 (de) * | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
US20060239956A1 (en) * | 2005-04-26 | 2006-10-26 | Lulu Henson | Preparation and use of hydrogels |
JPWO2007023729A1 (ja) * | 2005-08-23 | 2009-02-26 | 日産化学工業株式会社 | 徐放性製剤 |
EP1946780B1 (en) | 2005-11-11 | 2012-01-11 | Asahi Kasei Chemicals Corporation | Controlled release solid preparation |
GB0607534D0 (en) * | 2006-04-13 | 2006-05-24 | Univ London Pharmacy | Colonic drug delivery formulation |
EP2026766A1 (en) | 2006-05-17 | 2009-02-25 | Synthon B.V. | Tablet composition with a prolonged release of tamsulosin |
SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
CA2669324C (en) | 2006-11-13 | 2012-06-19 | Kyorin Pharmaceutical Co., Ltd. | Method for preparing sustained release tablet |
JPWO2008081829A1 (ja) | 2006-12-27 | 2010-04-30 | アステラス製薬株式会社 | 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーe |
KR100885029B1 (ko) * | 2007-02-07 | 2009-02-23 | 지엘팜텍 주식회사 | 경구투여용 서방성 삼중정제 |
DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
US20090036414A1 (en) * | 2007-08-02 | 2009-02-05 | Mutual Pharmaceutical Company, Inc. | Mesalamine Formulations |
EP2047847A1 (en) | 2007-10-12 | 2009-04-15 | KRKA, tovarna zdravil, d.d., Novo mesto | Solid pharmaceutical composition comprising tamsulosin |
US8312931B2 (en) * | 2007-10-12 | 2012-11-20 | Baker Hughes Incorporated | Flow restriction device |
US7942206B2 (en) | 2007-10-12 | 2011-05-17 | Baker Hughes Incorporated | In-flow control device utilizing a water sensitive media |
US8096351B2 (en) * | 2007-10-19 | 2012-01-17 | Baker Hughes Incorporated | Water sensing adaptable in-flow control device and method of use |
US7784543B2 (en) * | 2007-10-19 | 2010-08-31 | Baker Hughes Incorporated | Device and system for well completion and control and method for completing and controlling a well |
US7891430B2 (en) | 2007-10-19 | 2011-02-22 | Baker Hughes Incorporated | Water control device using electromagnetics |
US7775271B2 (en) | 2007-10-19 | 2010-08-17 | Baker Hughes Incorporated | Device and system for well completion and control and method for completing and controlling a well |
US7775277B2 (en) * | 2007-10-19 | 2010-08-17 | Baker Hughes Incorporated | Device and system for well completion and control and method for completing and controlling a well |
US7918272B2 (en) * | 2007-10-19 | 2011-04-05 | Baker Hughes Incorporated | Permeable medium flow control devices for use in hydrocarbon production |
US7913755B2 (en) | 2007-10-19 | 2011-03-29 | Baker Hughes Incorporated | Device and system for well completion and control and method for completing and controlling a well |
US7913765B2 (en) * | 2007-10-19 | 2011-03-29 | Baker Hughes Incorporated | Water absorbing or dissolving materials used as an in-flow control device and method of use |
US8544548B2 (en) * | 2007-10-19 | 2013-10-01 | Baker Hughes Incorporated | Water dissolvable materials for activating inflow control devices that control flow of subsurface fluids |
US7789139B2 (en) | 2007-10-19 | 2010-09-07 | Baker Hughes Incorporated | Device and system for well completion and control and method for completing and controlling a well |
US7793714B2 (en) | 2007-10-19 | 2010-09-14 | Baker Hughes Incorporated | Device and system for well completion and control and method for completing and controlling a well |
US20090101354A1 (en) * | 2007-10-19 | 2009-04-23 | Baker Hughes Incorporated | Water Sensing Devices and Methods Utilizing Same to Control Flow of Subsurface Fluids |
US8069921B2 (en) * | 2007-10-19 | 2011-12-06 | Baker Hughes Incorporated | Adjustable flow control devices for use in hydrocarbon production |
US20090101344A1 (en) * | 2007-10-22 | 2009-04-23 | Baker Hughes Incorporated | Water Dissolvable Released Material Used as Inflow Control Device |
US7918275B2 (en) * | 2007-11-27 | 2011-04-05 | Baker Hughes Incorporated | Water sensitive adaptive inflow control using couette flow to actuate a valve |
EP2249811A1 (en) | 2008-01-25 | 2010-11-17 | Grünenthal GmbH | Pharmaceutical dosage form |
US7597150B2 (en) | 2008-02-01 | 2009-10-06 | Baker Hughes Incorporated | Water sensitive adaptive inflow control using cavitations to actuate a valve |
US8839849B2 (en) * | 2008-03-18 | 2014-09-23 | Baker Hughes Incorporated | Water sensitive variable counterweight device driven by osmosis |
US7992637B2 (en) * | 2008-04-02 | 2011-08-09 | Baker Hughes Incorporated | Reverse flow in-flow control device |
DE102008022520A1 (de) * | 2008-05-07 | 2009-11-12 | Bayer Animal Health Gmbh | Feste Arzneimittelformulierung mit verzögerter Freisetzung |
US8931570B2 (en) * | 2008-05-08 | 2015-01-13 | Baker Hughes Incorporated | Reactive in-flow control device for subterranean wellbores |
CA2723438C (en) | 2008-05-09 | 2016-10-11 | Gruenenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
US8113292B2 (en) | 2008-05-13 | 2012-02-14 | Baker Hughes Incorporated | Strokable liner hanger and method |
US8555958B2 (en) | 2008-05-13 | 2013-10-15 | Baker Hughes Incorporated | Pipeless steam assisted gravity drainage system and method |
US7762341B2 (en) * | 2008-05-13 | 2010-07-27 | Baker Hughes Incorporated | Flow control device utilizing a reactive media |
US8171999B2 (en) * | 2008-05-13 | 2012-05-08 | Baker Huges Incorporated | Downhole flow control device and method |
US7789152B2 (en) | 2008-05-13 | 2010-09-07 | Baker Hughes Incorporated | Plug protection system and method |
EP2161019A1 (en) | 2008-09-05 | 2010-03-10 | KRKA, D.D., Novo Mesto | Prolonged release multiparticulate pharmaceutical composition comprising paliperidone |
TWI478712B (zh) | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
US8465770B2 (en) | 2008-12-24 | 2013-06-18 | Synthon Bv | Low dose controlled release tablet |
NZ594311A (en) * | 2009-02-04 | 2013-05-31 | Astellas Pharma Inc | Pharmaceutical composition comprising tamsulosin and solifenacin for oral administration |
EP2255793A1 (en) | 2009-05-28 | 2010-12-01 | Krka Tovarna Zdravil, D.D., Novo Mesto | Pharmaceutical composition comprising tamsulosin |
US8132624B2 (en) * | 2009-06-02 | 2012-03-13 | Baker Hughes Incorporated | Permeability flow balancing within integral screen joints and method |
US8056627B2 (en) * | 2009-06-02 | 2011-11-15 | Baker Hughes Incorporated | Permeability flow balancing within integral screen joints and method |
US20100300675A1 (en) * | 2009-06-02 | 2010-12-02 | Baker Hughes Incorporated | Permeability flow balancing within integral screen joints |
US20100300674A1 (en) * | 2009-06-02 | 2010-12-02 | Baker Hughes Incorporated | Permeability flow balancing within integral screen joints |
US8151881B2 (en) * | 2009-06-02 | 2012-04-10 | Baker Hughes Incorporated | Permeability flow balancing within integral screen joints |
BR112012001244A2 (pt) | 2009-07-22 | 2020-12-08 | Gruünenthal Gmbh | Forma de dosagem resitente à adulteração, seu processo de produção, e embalagem contendo tal forma |
WO2011009602A1 (en) | 2009-07-22 | 2011-01-27 | Grünenthal GmbH | Hot-melt extruded controlled release dosage form |
AU2010314992B2 (en) | 2009-11-09 | 2016-09-15 | Spotlight Technology Partners Llc | Polysaccharide based hydrogels |
CA2780274C (en) | 2009-11-09 | 2018-06-26 | Spotlight Technology Partners Llc | Fragmented hydrogels |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
US9579285B2 (en) | 2010-02-03 | 2017-02-28 | Gruenenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of an extruder |
KR101484382B1 (ko) * | 2010-02-24 | 2015-01-19 | 조에티스 엘엘씨 | 수의학적 조성물 |
WO2011122524A1 (ja) | 2010-03-29 | 2011-10-06 | アステラス製薬株式会社 | 放出制御医薬組成物 |
US8877214B2 (en) | 2010-03-29 | 2014-11-04 | Astellas Pharma Inc. | Pharmaceutical composition for modified release |
AR082862A1 (es) | 2010-09-02 | 2013-01-16 | Gruenenthal Gmbh | Forma de dosificacion resistente a alteracion que comprende un polimero anionico |
RU2604676C2 (ru) | 2010-09-02 | 2016-12-10 | Грюненталь Гмбх | Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль |
US9011912B2 (en) | 2010-10-07 | 2015-04-21 | Abon Pharmaceuticals, Llc | Extended-release oral dosage forms for poorly soluble amine drugs |
MY166034A (en) | 2010-12-22 | 2018-05-21 | Purdue Pharma Lp | Encased tamper resistant controlled release dosage forms |
JP5638151B2 (ja) | 2010-12-23 | 2014-12-10 | パーデュー、ファーマ、リミテッド、パートナーシップ | 不正加工抵抗性の(tamperresistant)固形経口剤形 |
KR102027912B1 (ko) | 2011-02-15 | 2019-10-02 | 지엘팜텍주식회사 | 경구투여용 탐술로신 또는 이의 약제학적으로 허용되는 염을 포함하는 서방성 삼중정제 |
RU2451680C1 (ru) | 2011-02-21 | 2012-05-27 | Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" | Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство |
BR112013031209B1 (pt) | 2011-06-07 | 2020-11-24 | Gelesis Llc | Metodo para produzir hidrogeis |
BR112014002022A2 (pt) | 2011-07-29 | 2017-02-21 | Gruenenthal Gmbh | comprimido resistente à violação proporcionando liberação de fármaco imediata |
PT2736497T (pt) | 2011-07-29 | 2017-11-30 | Gruenenthal Gmbh | Comprimido resistente a adulteração proporcionando libertação imediata de fármaco |
PE20141189A1 (es) | 2011-10-21 | 2014-09-24 | Takeda Pharmaceutical | Preparacion de liberacion sostenida |
US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
CA2864949A1 (en) | 2012-02-28 | 2013-09-06 | Grunenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
WO2013147135A1 (ja) * | 2012-03-30 | 2013-10-03 | アステラス製薬株式会社 | 放出制御医薬組成物 |
ES2692944T3 (es) | 2012-04-18 | 2018-12-05 | Grünenthal GmbH | Forma de dosificación farmacéutica resistente a la manipulación y resistente a la descarga rápida de la dosis |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
EP2934251B1 (en) * | 2012-12-21 | 2021-03-17 | Société des Produits Nestlé S.A. | Device for producing milk foam |
US8999393B1 (en) | 2013-01-09 | 2015-04-07 | Edgemont Pharmaceuticals Llc | Sustained release formulations of lorazepam |
US9149533B2 (en) | 2013-02-05 | 2015-10-06 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
MX2015016254A (es) | 2013-05-29 | 2016-04-20 | Gruenenthal Gmbh | Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal. |
MX371432B (es) | 2013-05-29 | 2020-01-30 | Gruenenthal Gmbh | Forma de dosificacion resistente al uso indebido que contiene una o mas particulas. |
CN105431144A (zh) | 2013-06-05 | 2016-03-23 | 思康脑侒股份有限公司 | 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合 |
US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
CN105934241B (zh) | 2013-11-26 | 2020-06-05 | 格吕伦塔尔有限公司 | 通过低温研磨制备粉末状药物组合物 |
WO2015173195A1 (en) | 2014-05-12 | 2015-11-19 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
AU2015266117A1 (en) | 2014-05-26 | 2016-11-24 | Grunenthal Gmbh | Multiparticles safeguarded against ethanolic dose-dumping |
WO2015196054A1 (en) | 2014-06-20 | 2015-12-23 | Gelesis, Llc | Methods for treating overweight or obesity |
EP3881829A1 (en) | 2014-11-07 | 2021-09-22 | Sublimity Therapeutics Limited | Compositions comprising cyclosporin |
US10179824B2 (en) | 2015-01-29 | 2019-01-15 | Gelesis Llc | Method for producing hydrogels coupling high elastic modulus and absorbance |
US20190125678A1 (en) | 2015-01-30 | 2019-05-02 | Mylan, Inc. | Sustained-Release Oral Dosage Forms for Low Aqueous Solubility Compounds |
CN107889459A (zh) | 2015-04-24 | 2018-04-06 | 格吕伦塔尔有限公司 | 具有立即释放和对溶剂萃取的抗性的抗篡改剂型 |
TWI722988B (zh) * | 2015-06-05 | 2021-04-01 | 瑩碩生技醫藥股份有限公司 | 緩釋性醫藥組合物及其製備方法 |
US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
US9675585B1 (en) | 2016-03-24 | 2017-06-13 | Ezra Pharma | Extended release pharmaceutical formulations |
US9687475B1 (en) | 2016-03-24 | 2017-06-27 | Ezra Pharma Llc | Extended release pharmaceutical formulations with controlled impurity levels |
CN105770866A (zh) * | 2016-04-08 | 2016-07-20 | 王夕花 | 一种缓释型降糖药物组合物及其制备方法 |
US20190307696A1 (en) | 2016-04-25 | 2019-10-10 | Synthon B.V. | Tablets comprising mirabegron and solifenacin |
WO2017186598A1 (en) | 2016-04-25 | 2017-11-02 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
WO2017189422A1 (en) | 2016-04-25 | 2017-11-02 | Gelesis, Llc. | Method for treating constipation |
WO2017222575A1 (en) | 2016-06-23 | 2017-12-28 | Collegium Pharmaceutical, Inc. | Process of making more stable abuse-deterrent oral formulations |
US10478399B2 (en) | 2017-10-12 | 2019-11-19 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
EP3694492A1 (en) | 2017-10-12 | 2020-08-19 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
EP3292864A1 (en) | 2017-10-12 | 2018-03-14 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
WO2019076966A1 (en) | 2017-10-17 | 2019-04-25 | Synthon B.V. | TABLETS COMPRISING TAMSULOSIN AND SOLIFENACIN |
WO2021153716A1 (en) * | 2020-01-31 | 2021-08-05 | Nippon Shinyaku Co., Ltd. | Controlled release composition |
CN111728949B (zh) * | 2020-07-17 | 2022-10-04 | 广州帝奇医药技术有限公司 | 一种难溶性药物口服缓释组合物及其制备方法 |
WO2022117594A1 (en) | 2020-12-01 | 2022-06-09 | Adamed Pharma S.A. | Orally-administered preparation containing solifenacin and tamsulosin |
JP2023553202A (ja) | 2020-12-08 | 2023-12-20 | ルミナント バイオテク コーポレーション リミテッド | 動物に物質を送達するための装置および方法の改善 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3065143A (en) * | 1960-04-19 | 1962-11-20 | Richardson Merrell Inc | Sustained release tablet |
BR6570825D0 (pt) * | 1964-07-04 | 1973-08-16 | Shiryo Kogyo Co Inc Nippon | Processo para produzir granulos cristalizados a partir de solucoes de acucares e outros cristaloides |
US3458622A (en) * | 1967-04-07 | 1969-07-29 | Squibb & Sons Inc | Controlled release tablet |
US3619292A (en) * | 1968-07-15 | 1971-11-09 | Penick & Ford Ltd | Tablets and method of forming |
JPS51135900A (en) * | 1975-05-19 | 1976-11-25 | Kao Corp | Method for prod uction of the stable sodium percarbonate |
US4126672A (en) * | 1976-02-04 | 1978-11-21 | Hoffmann-La Roche Inc. | Sustained release pharmaceutical capsules |
US4111201A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for delivering selected beneficial agents having varying degrees of solubility |
GB1579818A (en) * | 1977-06-07 | 1980-11-26 | Yamanouchi Pharma Co Ltd | Nifedipine-containing solid preparation composition |
CA1146866A (en) * | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
JPS5649314A (en) | 1979-07-05 | 1981-05-02 | Yamanouchi Pharmaceut Co Ltd | Lasting pharmaceutical composition having prolonged action and its preparation |
GB2108517B (en) | 1981-06-12 | 1985-06-12 | Nat Res Dev | Hydrogels |
JPS58189121A (ja) * | 1982-04-30 | 1983-11-04 | Ajinomoto Co Inc | インシユリン投与賦活剤 |
US4571333A (en) * | 1983-06-14 | 1986-02-18 | Syntex (U.S.A.) Inc. | Controlled release naproxen and naproxen sodium tablets |
US5002776A (en) * | 1983-12-22 | 1991-03-26 | Elan Corporation, Plc | Controlled absorption diltiazem formulations |
US4629621A (en) * | 1984-07-23 | 1986-12-16 | Zetachron, Inc. | Erodible matrix for sustained release bioactive composition |
US4704285A (en) * | 1985-11-18 | 1987-11-03 | The Dow Chemical Company | Sustained release compositions comprising hydroxypropyl cellulose ethers |
IE63321B1 (en) * | 1986-02-03 | 1995-04-05 | Elan Corp Plc | Drug delivery system |
US4764378A (en) * | 1986-02-10 | 1988-08-16 | Zetachron, Inc. | Buccal drug dosage form |
SE8601624D0 (sv) | 1986-04-11 | 1986-04-11 | Haessle Ab | New pharmaceutical preparations |
ATE71833T1 (de) | 1986-11-03 | 1992-02-15 | Schering Corp | Labetalol tablette mit verzoegerter wirkstoffabgabe. |
US4940580A (en) | 1986-11-03 | 1990-07-10 | Schering Corporation | Sustained release labetalol tablets |
JPS63151353A (ja) * | 1986-12-15 | 1988-06-23 | Oogawara Kakoki Kk | ワツクスコ−テイングマイクロカプセルの製造方法 |
US5026560A (en) * | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
US5015479A (en) * | 1987-02-02 | 1991-05-14 | Seamus Mulligan | Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine |
US4968508A (en) | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
US4904474A (en) * | 1988-01-25 | 1990-02-27 | Alza Corporation | Delivery of drug to colon by oral disage form |
JPH0283316A (ja) | 1988-09-20 | 1990-03-23 | Shin Etsu Chem Co Ltd | 徐放性錠剤 |
IT1230576B (it) * | 1988-10-20 | 1991-10-28 | Angeli Inst Spa | Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon |
US5128132A (en) * | 1988-11-22 | 1992-07-07 | Parnell Pharmaceuticals, Inc. | Eriodictyon compositions and methods for treating internal mucous membranes |
IL92966A (en) * | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
IE69555B1 (en) | 1989-01-31 | 1996-10-02 | Int Pharma Agentur | An erosion-controlled release system for active agents and a process for its preparation |
HU203041B (en) | 1989-03-14 | 1991-05-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin |
PT93637A (pt) * | 1989-04-20 | 1990-11-20 | Procter & Gamble | Metodo para o tratamento de desordens funcionais intestinais/colonicas, especialmente o sindrome de irritacao intestinal |
JPH0334927A (ja) * | 1989-06-29 | 1991-02-14 | Teikoku Seiyaku Kk | 潰瘍性大腸炎およびクローン病治療用経口投与組成物 |
US5000962A (en) * | 1989-08-25 | 1991-03-19 | Schering Corporation | Long acting diltiazem formulation |
US5178866A (en) * | 1990-03-23 | 1993-01-12 | Alza Corporation | Dosage form for delivering drug to the intestine |
US5252318A (en) | 1990-06-15 | 1993-10-12 | Allergan, Inc. | Reversible gelation compositions and methods of use |
US5156850A (en) * | 1990-08-31 | 1992-10-20 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
SE9003904D0 (sv) | 1990-12-07 | 1990-12-07 | Astra Ab | Method for the manufacture of a pharmaceutical dosage form |
US5273758A (en) * | 1991-03-18 | 1993-12-28 | Sandoz Ltd. | Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms |
JP2916290B2 (ja) * | 1991-03-22 | 1999-07-05 | 帝國製薬株式会社 | 生理活性ポリペプチド含有大腸崩壊経口製剤 |
JPH05255125A (ja) * | 1992-02-29 | 1993-10-05 | Upjohn Co:The | 徐放性製剤およびその製法 |
JPH05262767A (ja) | 1992-03-19 | 1993-10-12 | Takeda Chem Ind Ltd | 持続性製剤 |
WO1994001483A1 (en) | 1992-07-02 | 1994-01-20 | Collagen Corporation | Biocompatible polymer conjugates |
DE4226753A1 (de) * | 1992-08-13 | 1994-02-17 | Basf Ag | Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen |
CZ291495B6 (cs) * | 1992-09-18 | 2003-03-12 | Yamanouchi Pharmaceutical Co., Ltd. | Hydrogelotvorný farmaceutický přípravek s prodlouženým uvolňováním |
PT621032E (pt) * | 1993-04-23 | 2001-01-31 | Novartis Ag | Dispositivo de distribuicao de libertacao controlada de farmaco |
TWI478712B (zh) * | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
-
1993
- 1993-09-10 CZ CZ1995679A patent/CZ291495B6/cs not_active IP Right Cessation
- 1993-09-10 HU HU9500808A patent/HU226456B1/hu unknown
- 1993-09-10 RU RU95109153/14A patent/RU2121830C1/ru active
- 1993-09-10 AU AU49838/93A patent/AU682827B2/en not_active Expired
- 1993-09-10 SK SK338-95A patent/SK281042B6/sk not_active IP Right Cessation
- 1993-09-10 ES ES93919648T patent/ES2179829T3/es not_active Expired - Lifetime
- 1993-09-10 KR KR1019950701051A patent/KR100355130B1/ko not_active IP Right Cessation
- 1993-09-10 PL PL93308137A patent/PL175026B1/pl unknown
- 1993-09-10 US US08/403,752 patent/US6436441B1/en not_active Expired - Fee Related
- 1993-09-10 DK DK93919648T patent/DK0661045T3/da active
- 1993-09-10 DE DE69332081T patent/DE69332081T2/de not_active Expired - Lifetime
- 1993-09-10 RO RO95-00542A patent/RO112991B1/ro unknown
- 1993-09-10 PT PT93919648T patent/PT661045E/pt unknown
- 1993-09-10 JP JP06507964A patent/JP3140465B2/ja not_active Expired - Lifetime
- 1993-09-10 CA CA002144077A patent/CA2144077C/en not_active Expired - Lifetime
- 1993-09-10 NZ NZ255579A patent/NZ255579A/en not_active IP Right Cessation
- 1993-09-10 WO PCT/JP1993/001297 patent/WO1994006414A1/ja active IP Right Grant
- 1993-09-10 EP EP93919648A patent/EP0661045B1/en not_active Expired - Lifetime
- 1993-09-10 AT AT93919648T patent/ATE219933T1/de active
- 1993-09-18 CN CN93117868A patent/CN1048397C/zh not_active Expired - Lifetime
-
1995
- 1995-03-15 BG BG99503A patent/BG61861B1/bg unknown
- 1995-03-16 FI FI951226A patent/FI115697B/sv not_active IP Right Cessation
- 1995-03-17 NO NO19951036A patent/NO312811B1/no not_active IP Right Cessation
-
2000
- 2000-11-01 US US09/702,880 patent/US6699503B1/en not_active Expired - Fee Related
-
2002
- 2002-12-20 US US10/323,810 patent/US20030203024A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI115697B (sv) | Förfarande för framställning av en hydrogel bildande långsamt frigörande preparat | |
EP1205190B1 (en) | Stable medicinal compositions for oral use using ferric oxides | |
US6562375B1 (en) | Stable pharmaceutical composition for oral use | |
US6893661B1 (en) | Controlled release formulations using intelligent polymers | |
US6419954B1 (en) | Tablets and methods for modified release of hydrophilic and other active agents | |
CZ20023470A3 (cs) | Farmaceutický prostředek | |
US7364755B2 (en) | Modified calcium phosphate excipient | |
US10039833B2 (en) | Drug delivery system to increase bioavailability | |
US20120039963A1 (en) | 3-(2-Dimethlaminomethyl Cyclohexyl)Phenol Retard Formulation | |
JP3598049B2 (ja) | ハイドロゲル徐放性製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Patent granted |
Ref document number: 115697 Country of ref document: FI |
|
PC | Transfer of assignment of patent |
Owner name: ASTELLAS PHARMA INC. Free format text: ASTELLAS PHARMA INC. |
|
MA | Patent expired |